Bacteria and bacterial rRNA genes associated with the development of colitis in IL-10-/- mice

Inflammatory Bowel Diseases

Volumn 14, Issue 8, 2008, Pages 1041-1050

  Ye, Jingxiao ^a   Lee, Jimmy W ^b   Presley, Laura L ^a   Bent, Elizabeth ^a   Wei, Bo ^c   Braun, Jonathan ^c   Schiller, Neal L ^b   Straus, Daniel S ^b   Borneman, James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacteria; Crohn's disease; IBD; IL 10 mice; rRNA genes

Indexed keywords

BACTERIAL ANTIGEN; INTERLEUKIN 10; RIBOSOME RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CLOSTRIDIUM; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FECES ANALYSIS; GENE IDENTIFICATION; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; IMMUNITY; LACHNOSPIRACEAE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; COLITIS; FLAGELLA; GENE EXPRESSION PROFILING; GENES, RRNA; INTERLEUKIN-10; MICE; MICE, INBRED C3H; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 49749147158     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20442     Document Type: Article

References (57)

1. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis. 2007;44:256-262.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastr. 2006;3:390-407.
3. Xavier RJ, Podolsky, DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
4. Rath HC. The role of endogenous bacterial flora: bystander or the necessary prerequisite? Eur J Gastroenterol Hepatol. 2003;15:615-620.
5. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
6. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991;338:771-774.
7. Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor RB, Sandborn WJ, eds. Kirsner's Inflammatory Bowel Diseases. Philadelphia: Elsevier. 2004: 138-162.
8. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128:891-906.
9. Kim SC, Tonkonogy SL, Karrasch T, et al. Dual-association of gnotobiotic IL-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel Dis. 2007;13:1457-1466.
10. Rath HC. Role of commensal bacteria in chronic experimental colitis: lessons from the HLA-B27 transgenic rat. Pathobiology. 2002/ 2003;70: 131-138.
11. Hoentjen F, Harmsen HJ, Braat H, et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut. 2003;52:1721-1727.
12. Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002;8:10-15.
13. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-1633.
14. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-1075.
15. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
16. Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv Exp Med Biol. 2006;579:209-218.
17. Borneman J, Becker JO, Bent E, et al. Identifying microorganisms involved in specific in situ functions: experimental design considerations for rRNA gene-based population studies and sequence-selective PCR assays. In: Hurst C, ed. Manual for Environmental Microbiology. 3rd ed. Washington, DC: ASM Press; 2007:748-757.
18. Borneman J, Becker JO. Identifying microorganisms involved in specific pathogen suppression in soil. Annu Rev Phytopathol. 2007;45:153-172.
19. Bristol IJ, Farmer MA, Cong Y, et al. Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis. 2000;6:290-302.
20. Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology. 2007;133:108-123.
21. Lytle C, Tod TJ, Kathy VT, et al. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis. 2005;11:231-243.
22. Bent E, Yin B, Figueroa A, et al. Development of a 9,600-clone procedure for oligonucleotide fingerprinting of rRNA genes: utilization to identify soil bacterial rRNA genes that correlate in abundance with the development of avocado root rot. J. Microbiol Method. 2006;67:171-180.
23. Valinsky L, Vedova GD, Scupham AJ, et al. Analysis of bacterial community composition by oligonucleotide fingerprinting of rRNA genes. Appl Environ Microbiol. 2002;68:3243-3250.
24. Figueroa A, Borneman J, Jiang T. Clustering binary fingerprint vectors with missing values for DNA array data analysis. J. Comput Biol. 2004;11:887-901.
25. Fu Q, Ruegger P, Bent E, et al. PRISE (PRImer SElector): software for designing sequence-selective PCR primers. J Microbiol Method. 2008; 72:263-267.
26. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389-3402.
27. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev. 1996;9:18-33.
28. Inglis TJ. Principia aetiologica: taking causality beyond Koch's postulates. J Med Microbiol. 2007;56:1419-1422.
29. Duck LW, Walter MR, Novak J, et al. Isolation of flagellated bacteria implicated in Crohn's disease. Inflamm Bowel Dis. 2007;13:1191-1201.
30. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis. 2007;13:524-530.
31. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028.
32. Berg DJ, Davidson N, Kühn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010-1020.
33. Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
34. Zhang M, Liu B, Zhang Y, et al. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J Clin Microbiol. 2007;45:496-500.
35. Fabia R, Ar'Rajab A, Johansson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 1993;54:248-255.
36. Matsuda H, Fujiyama Y, Andoh A, et al. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000;15:61-68.
37. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380-3389.
38. Fujita H, Eishi Y, Ishige I, et al. Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases. J Gastroenterol. 2002;37:509-516.
39. Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest. 2007; 87:1042-1054.
40. Scanlan PD, Shanahan F, O'Mahony C, et al. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol. 2006; 44:3980-3988.
41. Sokol H, Lepage P, Seksik P, et al. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol. 2006; 44:3172-3177.
42. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693.
43. Gophna U, Sommerfeld K, Gophna S, et al. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol. 2006;44:4136-4141.
44. Baumgart M, Dogan B, Rishniw M, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 2007;1:403-418.
45. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780-13785.
46. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-211.
47. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:106-111.
48. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384.
49. Ibnou-Zekri N, Blum S, Schiffrin EJ, et al. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect Immun. 2003;71: 428-436.
50. Peña JA, Li SY, Wilson PH, et al. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. Appl Environ Microbiol. 2004;70:558-568.
51. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after Ileo-caecal resection. Inflamm Bowel Dis. 2007;13:135-142.
52. Peña JA, Rogers AB, Ge Z, et al. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun. 2005;73:912-920.
53. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975-980.
54. O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther. 2001;15:1219-1225.
55. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311-1315.
56. Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol. 2007;42:1-15.
57. Saldanha AJ. Java Treeview - extensible visualization of microarray data. Bioinformatics. 2004;20:3246-3248.